The business minted an astounding 40% growth in tests and 26% revenue growth year over year. Oncotype DX Genomic Prostate Score currently has the opportunity to cater to 160,000 patients in the U.S. every year. We believe this is indicative of the huge potential for revenue growth that the company's Prostate Cancer test has in the U.S. Additionally, the company's colon cancer test helped it attain a global identity with more than 26,060 Oncotype DX test (in three major cancer types) results. Having established a strong foothold in the U.S., Genomic Health is now making considerable expansion in the international arena. On the flip side, growth in the cancer test business failed to boost Genomic Health's third-quarter results as both the top and the bottom line missed the Zacks Consensus Estimate. The company's cancer tests and studies are still in the early-to-mid stage of development and bear validation risks.